Takeda

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Takeda sits in the top decile of US sponsors by registered trial count (#88 of 15,742 sponsors by registered trial count).

408 total trials 49 currently recruiting 284 completed top decile by trial count

Takeda: 408 sponsored US clinical trials, 49 recruiting.

Takeda sponsors 408 registered US clinical trials on ClinicalTrials.gov, 49 of them currently recruiting, and 284 completed. 174 of these trials are in Phase 3-4 (later-stage) and 209 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteers, with 16 trials.

Top-decile sponsor footprint

Takeda ranks in the top decile of sponsors by registered trial count (#88 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 48/100

284 of 340 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

408 total, page 8 of 9

COMPLETED Phase 4

Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.

NCT00414102

COMPLETED Phase 2

Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy

NCT00760955

COMPLETED Phase 3

The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux

NCT00324974

COMPLETED Phase 3

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

NCT00321984

COMPLETED Phase 4

Safety of Ramelteon in Elderly Subjects

NCT00568789

TERMINATED Phase 3

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

NCT00376181

COMPLETED Phase 2

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

NCT00362115

COMPLETED Phase 3

Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

NCT00321737

COMPLETED Phase 3

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

NCT00328627

COMPLETED Phase 4

Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease

NCT00316992

COMPLETED Phase 3

Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.

NCT00286468

TERMINATED Phase 2

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00312286

TERMINATED Phase 2

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00117884

COMPLETED Phase 2

Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease

NCT00325728

COMPLETED Phase 3

Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus

NCT00286442

COMPLETED Phase 3

Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus

NCT00306384

COMPLETED Phase 3

Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia

NCT00286481

COMPLETED Phase 3

Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.

NCT00286429

COMPLETED Phase 2

Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels

NCT00813527

COMPLETED Phase 3

Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes

NCT00286455

COMPLETED Phase 3

Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00286494

COMPLETED Phase 3

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

NCT00255151

COMPLETED Phase 3

Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

NCT00255190

COMPLETED Phase 3

Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis

NCT00255164

COMPLETED Phase 3

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251719

COMPLETED Phase 3

Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

NCT00251745

COMPLETED Phase 3

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

NCT00251758

COMPLETED Phase 3

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251693

COMPLETED Phase 4

Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)

NCT00246909

TERMINATED Phase 3

Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia

NCT00263081

TERMINATED Phase 3

Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia

NCT00249899

COMPLETED Phase 3

Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia

NCT00249912

COMPLETED Phase 3

Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.

NCT00251680

COMPLETED Phase 3

Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol

NCT00143663

COMPLETED Phase 3

Efficacy & Safety of Resatorvid in Adults With Severe Sepsis

NCT00143611

COMPLETED Phase 3

Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia

NCT00143676

COMPLETED Phase 3

Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.

NCT00247390

COMPLETED Phase 2

Safety and Efficacy of Ramelteon in Healthy Subjects

NCT00671190

COMPLETED Phase 2

Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy

NCT00229437

TERMINATED Phase 3

Efficacy of Ramelteon in Adults With Chronic Insomnia

NCT00672724

COMPLETED Phase 3

Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia

NCT00487994

COMPLETED Phase 2

Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

NCT00762736

COMPLETED Phase 4

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

NCT00672919

COMPLETED Phase 3

Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.

NCT00225264

COMPLETED Phase 2

Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease

NCT00672802

COMPLETED Phase 2

Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea

NCT00672061

COMPLETED Phase 3

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

NCT00225277

COMPLETED Phase 2

Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse

NCT00671632

COMPLETED Phase 3

Efficacy of Ramelteon in Subjects With Chronic Insomnia

NCT00671086

COMPLETED Phase 3

Study of Efficacy of Ramelteon in Adults With Chronic Insomnia

NCT00671125

← Previous Page 8 of 9 Next →

What is open in the Takeda pipeline

49 recruiting of 408 indexed (12% open); 284 completed (70%).

Phase mix: 174 late (III/IV) vs 209 early (I/II) (balanced across stages).

Top condition: Healthy Volunteers (16 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Takeda: open-pipeline peers nationwide

Peers matched on 408 registered trials and 12% open enrollment, not the therapeutic-area sidebar.

Takeda sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 10%15%20%25% Total trials Recruiting share TakedaUniversity of Kansas Medical CenterCase Comprehensive Cancer CenterUniversity of NebraskaSt. Jude Children's Research HospitalArcus BiosciencesArdelyxKyowa Kirin Co.East Carolina University
Takeda sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Takeda sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 408 trials (± recruiting share)

Sponsors near 12% open enrollment (± trial volume)

What to do with this Takeda page

408 registered trials is a research-attention snapshot, not an endorsement of Takeda or any single study.

  • 49 of Takeda's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy Volunteers is the condition Takeda studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Volunteers trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Takeda pipeline card: 408 registered trials from official public datasets.Report a data error.